These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 31335153)

  • 21. Physiological Buffer Effects in Drug Supersaturation - A Mechanistic Study of Hydroxypropyl Cellulose as Precipitation Inhibitor.
    Niederquell A; Stoyanov E; Kuentz M
    J Pharm Sci; 2023 Jul; 112(7):1897-1907. PubMed ID: 36813134
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Accelerating the dissolution of enteric coatings in the upper small intestine: evolution of a novel pH 5.6 bicarbonate buffer system to assess drug release.
    Varum FJ; Merchant HA; Goyanes A; Assi P; Zboranová V; Basit AW
    Int J Pharm; 2014 Jul; 468(1-2):172-7. PubMed ID: 24727141
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Regulating the pH of bicarbonate solutions without purging gases: Application to dissolution testing of enteric coated tablets, pellets and microparticles.
    Scott N; Patel K; Sithole T; Xenofontos K; Mohylyuk V; Liu F
    Int J Pharm; 2020 Jul; 585():119562. PubMed ID: 32565282
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Toward Biopredictive Dissolution for Enteric Coated Dosage Forms.
    Al-Gousous J; Amidon GL; Langguth P
    Mol Pharm; 2016 Jun; 13(6):1927-36. PubMed ID: 27139040
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Dissolution of a Biopharmaceutics Classification System Class II Free Acid from Immediate Release Tablets Containing a Microenvironmental pH Modulator: Comparison of a Biorelevant Bicarbonate Buffering System with Phosphate Buffers.
    Haznar-Garbacz D; Hoc D; Garbacz G; Lachman M; Słomińska D; Romański M
    AAPS PharmSciTech; 2022 Jul; 23(6):203. PubMed ID: 35882674
    [TBL] [Abstract][Full Text] [Related]  

  • 26. HPMCAS as an effective precipitation inhibitor in amorphous solid dispersions of the poorly soluble drug candesartan cilexetil.
    Pinto JMO; Leão AF; Riekes MK; França MT; Stulzer HK
    Carbohydr Polym; 2018 Mar; 184():199-206. PubMed ID: 29352911
    [TBL] [Abstract][Full Text] [Related]  

  • 27. In Silico Modeling Approach for the Evaluation of Gastrointestinal Dissolution, Supersaturation, and Precipitation of Posaconazole.
    Hens B; Pathak SM; Mitra A; Patel N; Liu B; Patel S; Jamei M; Brouwers J; Augustijns P; Turner DB
    Mol Pharm; 2017 Dec; 14(12):4321-4333. PubMed ID: 28817288
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Model-Based Analysis of Biopharmaceutic Experiments To Improve Mechanistic Oral Absorption Modeling: An Integrated in Vitro in Vivo Extrapolation Perspective Using Ketoconazole as a Model Drug.
    Pathak SM; Ruff A; Kostewicz ES; Patel N; Turner DB; Jamei M
    Mol Pharm; 2017 Dec; 14(12):4305-4320. PubMed ID: 28771009
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Supersaturation and Precipitation Applicated in Drug Delivery Systems: Development Strategies and Evaluation Approaches.
    Gan Y; Baak JPA; Chen T; Ye H; Liao W; Lv H; Wen C; Zheng S
    Molecules; 2023 Feb; 28(5):. PubMed ID: 36903470
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Use of bicarbonate buffer systems for dissolution characterization of enteric-coated proton pump inhibitor tablets.
    Shibata H; Yoshida H; Izutsu K; Goda Y
    J Pharm Pharmacol; 2016 Apr; 68(4):467-74. PubMed ID: 27019275
    [TBL] [Abstract][Full Text] [Related]  

  • 31. New supersaturating drug delivery system as strategy to improve apparent solubility of candesartan cilexetil in biorelevant medium.
    Pinto JMO; Leão AF; Alves GF; Mendes C; França MT; Fernandes D; Stulzer HK
    Pharm Dev Technol; 2020 Jan; 25(1):89-99. PubMed ID: 31583925
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Enhanced oral delivery of celecoxib via the development of a supersaturable amorphous formulation utilising mesoporous silica and co-loaded HPMCAS.
    Lainé AL; Price D; Davis J; Roberts D; Hudson R; Back K; Bungay P; Flanagan N
    Int J Pharm; 2016 Oct; 512(1):118-125. PubMed ID: 27543354
    [TBL] [Abstract][Full Text] [Related]  

  • 33. In Vivo Predictive Dissolution: Comparing the Effect of Bicarbonate and Phosphate Buffer on the Dissolution of Weak Acids and Weak Bases.
    Krieg BJ; Taghavi SM; Amidon GL; Amidon GE
    J Pharm Sci; 2015 Sep; 104(9):2894-904. PubMed ID: 25980464
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Predicting the gastrointestinal behaviour of modified-release products: utility of a novel dynamic dissolution test apparatus involving the use of bicarbonate buffers.
    Merchant HA; Goyanes A; Parashar N; Basit AW
    Int J Pharm; 2014 Nov; 475(1-2):585-91. PubMed ID: 25195730
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Mesoporous silica-based dosage forms improve bioavailability of poorly soluble drugs in pigs: case example fenofibrate.
    O'Shea JP; Nagarsekar K; Wieber A; Witt V; Herbert E; O'Driscoll CM; Saal C; Lubda D; Griffin BT; Dressman JB
    J Pharm Pharmacol; 2017 Oct; 69(10):1284-1292. PubMed ID: 28631822
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Precipitation in the small intestine may play a more important role in the in vivo performance of poorly soluble weak bases in the fasted state: case example nelfinavir.
    Shono Y; Jantratid E; Dressman JB
    Eur J Pharm Biopharm; 2011 Oct; 79(2):349-56. PubMed ID: 21527341
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Use of a physiologic bicarbonate buffer system for dissolution characterization of ionizable drugs.
    McNamara DP; Whitney KM; Goss SL
    Pharm Res; 2003 Oct; 20(10):1641-6. PubMed ID: 14620520
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Increasing the Robustness of Biopharmaceutical Precipitation Assays - Part II: Recommendations on the use of FaSSIF.
    Krollik K; Lehmann A; Wagner C; Kaidas J; Bülhoff J; Kubas H; Weitschies W
    J Pharm Sci; 2022 Jan; 111(1):155-163. PubMed ID: 34461113
    [TBL] [Abstract][Full Text] [Related]  

  • 39. In vitro dissolution of proton-pump inhibitor products intended for paediatric and geriatric use in physiological bicarbonate buffer.
    Liu F; Shokrollahi H
    Int J Pharm; 2015 May; 485(1-2):152-9. PubMed ID: 25746736
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Solubility vs Dissolution in Physiological Bicarbonate Buffer.
    Claussen F; Al-Gousous J; Salehi N; Garcia MA; Amidon GL; Langguth P
    Pharm Res; 2024 May; 41(5):937-945. PubMed ID: 38698196
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.